CSA stitches ClinicalTrials.gov, openFDA, SEC EDGAR, and FDA substance identity into one asset ↔ sponsor ↔ ticker graph — with a forward catalyst calendar. Anyone can pull one registry; the join and the freshness are the product.
One-time snapshot · CSV + JSON · public-domain sources · monthly editions
v1 scope: active · industry-sponsored · Phase 3 · cardiometabolic, oncology, immunology — 2,268 trials → 1,841 resolved assets.
Codes, INNs, salts, brands, and combinations collapse to a canonical asset keyed by its FDA-registered active-moiety UNII set — authoritative, not fuzzy. A post-clustering guard makes it hold by construction.
Trial sponsors resolve to the current tradable owner — through acquisitions, to the primary US listing, not the OTC grey line. Comparator and background drugs are flagged, never misattributed.
Two precision-first channels: SEC 8-K disclosure text (PDUFA, AdComm, announced readouts) and ClinicalTrials.gov protocol readouts. Every row carries its source and trial id.
source + nct_id per rowA handful of real upcoming catalysts from the dataset. The full snapshot carries 2,103 forward events across 139 listed sponsors, each with a confidence grade and a source URL to re-verify.
| Date | Ticker | Asset | Event | Window | Confidence |
|---|---|---|---|---|---|
| 2026-07-25 | BMY | deucravacitinib | Readout | Jul 25, 2026 | medium |
| 2026-07-27 | REGN | fianlimab | Readout | Jul 27, 2026 | medium |
| 2026-07-31 | JAZZ | zanidatamab | Readout | Jul 31, 2026 | medium |
| 2026-09-30 | AZN | datopotamab deruxtecan | Readout | Sep 30, 2026 | medium |
| 2026-11-30 | NAMS | obicetrapib | Readout | Nov 2026 | medium |
| 2026-12-21 | PFE | ritlecitinib | Readout | Dec 21, 2026 | medium |
| 2027-12-01 | RVMD | daraxonrasib | Readout | Dec 1, 2027 | medium |
| 2028-08-24 | NVS | pelacarsen | Readout | Aug 24, 2028 | medium |
Subscribers get the delta feed too — MOVED (a slipped date), ADDED, FIRED, REMOVED — the change report is the recurring product.
Kick the tires first — explore the free 150-catalyst sample on Kaggle or Hugging Face.
asset_master · catalyst_calendar · regulatory_events · scope manifest — CSV + JSON.
Secure card checkout via Stripe · delivered instantly after payment.
Need an invoice or crypto? Contact us.
Data, not investment advice. CSA is information, not a recommendation to buy, sell, or hold any security. Estimated catalyst dates (e.g. protocol primary-completion dates) routinely slip and are graded by confidence — verify anything material against the source URL on each row before acting.
Active, industry-sponsored, Phase 3 interventional trials in cardiometabolic, oncology and immunology: 2,268 trials resolved to 1,841 assets, 627 of them the sponsor's own asset linked to a listed ticker, plus 2,103 forward catalysts across 139 sponsors. CSV + JSON with a scope manifest. Phase 2 and more areas are the roadmap.
Assets are keyed by their FDA-registered active-moiety UNII set, not fuzzy name matching, and a post-clustering guard means no asset spans two different active moieties — audited to 0 cross-molecule merges on the full run. Uncertain pairs are held for review rather than merged. Precision is the guarantee that matters; a wrong link is the costly error.
Yes. Every primary source is U.S. Government / public domain: ClinicalTrials.gov, openFDA, SEC EDGAR, GSRS/UNII. No license-encumbered source (DrugBank, ChEMBL, MedDRA) is included. Your commercial license ships inside the archive.
They're graded. Company-disclosed exact dates (from 8-Ks) rank above protocol primary-completion estimates, which routinely slip — so they carry a lower confidence and are never presented as commitments. Every row links to its source_url so you can re-verify.
No. CSA is a dataset — information, not advice or a recommendation. See the notice above and the license inside the archive.
API access, more coverage, an enterprise license, or an invoice — reach the desk at roasterdb@proton.me.
Thanks — we'll reply within one business day.